Respiratory in Medical Technology

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... further strengthen Schering-Plough's portfolio of respiratory products." Combination products ... allergic rhinitis, sore throat, and upper respiratory infection. Please see additional ... events reported with FORADIL AEROLIZER were upper respiratory infection, back pain, and sore throat. ...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a ... ) Axentis Pharma is a respiratory specialty pharmaceutical company whose core ... for unmet medical needs, including chronic respiratory infections of the lung. In the case ...

PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies

... RRT, director of clinical development at PARI respiratory Equipment. The Sutherland et al. study, ... listed in the package insert. About PARI respiratory Equipment, Inc. PARI is a leading worldwide ... is to improve the lives of those affected by respiratory diseases and those who care for them. Maker ...

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

... study designed to assess the burden of respiratory syncytial virus (RSV) among preterm infants ... severe RSV infections, the leading cause of lower respiratory tract infections in U.S. infants. RSV is the most common respiratory infection in infancy or childhood. Approximately ...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

... stated Prof. Jurgen Behr, head of the Division of respiratory Disease at the Ludwig Maximilians University, ... vascular diseases, inhalation of toxic fumes, and respiratory tract infections. Bronchiolitis obliterans ... and once it develops, most patients die of respiratory failure within 5 years. About PARI Pharma ...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

... against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, ... of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as ... are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and ...

FDA Advisory Panel Recommends Approval of the SEDASYS(R) System

... today announced that the Anesthesiology and respiratory Therapy Devices Advisory Committee of the U.S. ... patient's needs. The Anesthesiology and respiratory Therapy Devices Advisory Committee voted 8 to 2 ... of over-sedation (oxygen desaturation and low respiratory rate/apnea), guided by continual monitoring and ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma or ... may result in adverse cardiovascular events. respiratory depression is the primary risk of mu-opioid agonists. respiratory depression occurs more frequently in elderly or ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

... Alexander Moeller, head of the Research Division, respiratory Medicine at the University Children's Hospital ... potential for the treatment of lower and upper respiratory diseases, such as asthma or sinusitis. ... trials for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments ...

Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma

... exacerbations) and emergency room visits for respiratory symptoms in adults with severe asthma who ... 84% reduction in emergency room visits for respiratory symptoms 36% reduction in patients ... lost from work/school or other activities due to respiratory symptoms In the period ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... most commonly occurring adverse events were upper respiratory tract infections, rash and urinary tract ... frequently than with placebo (n=614) were upper respiratory infection (20% CIMZIA, 13% placebo), urinary ... with concomitant methotrexate (n=324) were upper respiratory tract infection (6% CIMZIA, 2% placebo), headache ...

MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants

... in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical ... J. Escobar. RSV is a leading cause of viral respiratory infection among preterm infants. Although ... between 33 and 36 weeks GA have under-developed respiratory and immune systems, putting them at heightened ...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

... -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has ... innovative treatment for infections of the respiratory tract in patients with cystic fibrosis that is ... marketed treatments for infections of the respiratory tract in patients with cystic fibrosis. ...

Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet

... therapeutic class in the management of allergic respiratory disorders. Stallergenes has been consolidating ... In Europe, on average, almost 40% of respiratory allergic conditions are caused by house dust ... of the world's population currently suffers from respiratory allergic symptoms (rhinoconjunctivitis, rhinitis ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... agonists are contraindicated (i.e., significant respiratory depression, acute or severe bronchial asthma or ... Due to its mu-opioid receptor agonism, respiratory depression is a possible adverse event of ... accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive ...

Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

... common being nasopharyngitis, sinusitis and upper respiratory tract infection. Two patients who were treated ... reactions (45%), viral infections (23%), upper respiratory tract infection (20%), sinus infection (16%), ... central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve ...

MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine

... month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease ... healthy infants and children. "RSV is a serious respiratory disease that can have significant effects on ...

Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI

... As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through ... and operates a specialty business focused on respiratory and allergy therapies. For more information about ... delivered by nebulization to COPD patients. respiratory Medicine, 2008, 102, 189-197. 5. Data to be ...

Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

... in the therapeutic areas of infection, cancer and respiratory diseases, today announced that the Journal of ... of the drug as a front-line treatment for respiratory tract infections. (Logo: ... and CA-MRSA are causative pathogens for respiratory tract infections such as community acquired ...

Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications

... to U.S. patients with chronic and acute respiratory insufficiency which has the promise of reducing ... These technology platforms resolve a number of respiratory clinical needs and create a neurostimulation ... NeuRx DPS(TM) to slow the decline of a patient's respiratory function as measured by Forced Vital Capacity and ...

Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results

... director of Clinical Development at PARI respiratory Equipment. The trial demonstrated statistical ... European Medicines Agency (EMEA). About PARI respiratory Equipment, Inc. PARI is a leading worldwide ... is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of ...

AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six

... events reported were headache, pyrexia, upper respiratory tract infection, nasopharyngitis, ... school in 2003.(8) It is also the second leading respiratory disease to cause hospitalization in children ... include nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, ...

Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

... a vaccine candidate against Severe Acute respiratory Syndrome (SARS). The company also received ... Executive Officer of Novavax, Inc. Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first ...

Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients

... tightness, night-time awakenings, and the total respiratory symptom score, were all significantly improved in ... published in the February 2008 issue of respiratory Medicine, detailed pivotal Phase III data ... As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through ...

Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone

... symptoms, rescue albuterol use and St. George's respiratory Questionnaire (SGRQ). In this trial there was a ... As the U.S. leader in sales of nebulized respiratory medication, Dey, L.P. puts patients first through ... delivered by nebulization to COPD patients. respiratory Medicine, 2008, 102, 189-197 Media ...

Amikacin Inhale Shows Promising Results in Phase II Study

... Penetration of Amikacin Inhale in Lower respiratory Tract(4) This study evaluated Amikacin Inhale ... the epithelial surface (ELF) of the lower respiratory tract of the pneumonia-infected lung. Treatment ... concentrations in the ELF of the lower respiratory tract, including in the pneumonic area of the ...

Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants

... infants. RSV is a leading cause of viral respiratory infection among preterm infants. Approximately ... prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of ... Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny ...

Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

... Motavizumab Reduced Hospitalizations Due to respiratory Syncytial Virus by 83 Percent Compared to Placebo ... potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk ... in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management ...

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study

... being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading ... the flexibility allows the development of new respiratory therapies that are delivered to the lungs in a ... said Geoff A. Hunziker, President of eFlow LLC. respiratory syncytial virus (RSV) is a highly contagious ...

RSV Researcher Makes Gains in Finding Treatments

... to the Centers for Disease Control. RSV, or respiratory syncytial virus -- is the leading cause of ... for the treatment of RSV infection, a serious respiratory viral disease that leads to the hospitalization ... of the study at the International Symposium on respiratory Viral Infections meeting in Singapore in early ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... 36 percent. The most common infections were upper respiratory tract infection and nasopharyngitis. ... (97 percent vs. 88 percent, respectively). respiratory disorders occurred more frequently in ... patients monitored for worsening of their respiratory status. Blood Glucose Testing: ORENCIA contains ...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

... a long-acting beta2-agonist, delivered to the respiratory tract using the Company's proprietary Tempo(R) ... a long-acting beta2-agonist, delivered to the respiratory tract using MAP Pharmaceuticals' proprietary ... About Asthma and COPD Asthma is a chronic respiratory disorder that is characterized by inflammation ...

PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial

... of Clinical Development at PARI respiratory Equipment. "Our LC STAR is a fine particle ... Medicines Agency (EMEA). About PARI respiratory Equipment, Inc. PARI is a leading worldwide ... is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of ...

N30 Pharma Announces Successful Initiation of Human Studies With N30-201

... discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, ... be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute ... therapies for important unmet needs in respiratory diseases. N30's strategy focuses on ...

GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program

... to commence in 1H 2008. Darrell Baker, SVP GSK respiratory Medicines Development Centre said, "The program ... a significant unmet patient need. As a leader in respiratory medicine, GSK is leveraging years of experience ... across a number of therapeutic areas including respiratory disease, bacterial infections and ...

Replidyne Provides Strategic Update

... product candidate intended to treat adult respiratory tract infections including acute ... are often used as first line therapy in many respiratory and skin infections in adult and pediatric ... penem available to treat patients with community respiratory tract infections. About Clostridium difficile ...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the ... a conventional corticosteroid commonly used in respiratory disorders, or placebo. Eligible patients will ... company specializing in developing products for respiratory disorders, today announced that the first ...

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia

... "Antimicrobial resistance in important respiratory pathogens, such as the pneumococci, is a growing ... of death in the United States. CAP and other respiratory tract infections are caused by pathogens such ... development for the treatment of respiratory tract infections including CAP. For more ...

Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

... the Executive Care Center for Asthma, Allergy and respiratory Diseases at UCLA School of Medicine and study ... and practices." The study, conducted by the respiratory & Allergic Disease Foundation, recruited 40 ... visit http://www.cslbehring.com . About the respiratory & Allergic Disease Foundation ...

MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV

... standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high- risk infants. ... RSV infections. RSV can cause severe lower respiratory tract infections in preterm infants. However, ...